NCT00366080View on ClinicalTrials.gov

Effectiveness Of The Drug GSK189254 In Treating Patients With Narcolepsy

PHASE2TerminatedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Narcolepsy
Interventions
DRUG

GSK189254

Trial Locations (14)

14050

GSK Investigational Site, Berlin

19053

GSK Investigational Site, Schwerin

34613

GSK Investigational Site, Schwalmstadt

44789

GSK Investigational Site, Bochum

93053

GSK Investigational Site, Regensburg

A-6020

GSK Investigational Site, Innsbruck

A-1190

GSK Investigational Site, Vienna

02980

GSK Investigational Site, Espoo

2333 CL

GSK Investigational Site, Leiden

08035

GSK Investigational Site, Barcelona

08036

GSK Investigational Site, Barcelona

CB3 8RE

GSK Investigational Site, Cambridge

W1G 6BF

GSK Investigational Site, London

EH3 6HP

GSK Investigational Site, Edinburgh

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00366080 - Effectiveness Of The Drug GSK189254 In Treating Patients With Narcolepsy | Biotech Hunter | Biotech Hunter